Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Encouraging Data from Stem Cell Trial in Stroke Patients as Plans for Phase II Progress

Published: Tuesday, May 28, 2013
Last Updated: Tuesday, May 28, 2013
Bookmark and Share
Encouraging interim data from the world’s first clinical trial examining the safety of neural stem cell treatment in stroke patients has been reported by researchers ahead of an application for Phase II trials.

Updated interim data from the PISCES trial, which has seen the brains of ischaemic stroke patients injected with neural stem cells to test the safety and tolerability of the treatment, was presented to the 22nd European Stroke Conference in London on Tuesday 28 May.

Professor Keith Muir of the University of Glasgow, who is heading the trial of ReNeuron Group plc’s ReN001 stem cell therapy at the Southern General Hospital, Glasgow reported that data from the first nine patients treated has shown no cell-related or immunological adverse affects.

He added that most patients had experienced sustained modest reductions in neurological impairment compared to their pre-treatment baseline performance, accompanied by improvement in abilities to undertake day to day tasks.

              
A further two patients have been treated since the data were collated and the trial is now drawing to a close, with full results due to be published next year.

Meanwhile, plans are proceeding for a Phase II trial which will examine the efficacy of stem cell treatment in stroke patients and an application is expected to be submitted to the UK regulatory authorities in early July. If approved the Phase II trial is scheduled to commence later this year.

The Phase II trial will be a controlled multi-centre trial involving around 20 patients initially, all of whom will have suffered a stroke within a few weeks.

Professor Muir said: “We remain pleased and encouraged by the data emerging from the PISCES study. The data to date identify no safety issues with the ReN001 treatment – which is the primary focus of this Phase I trial.

“The evidence of functional improvement requires further investigation in a suitably designed Phase II efficacy study and we look forward to being a principal clinical site in that study when it commences.”

Michael Hunt, Chief Executive Officer of ReNeuron, said: “The PISCES study continues to yield encouraging results. Assuming the remaining required short-term follow up data confirm the good safety profile of the treatment, we will be able to move the ReN001 therapy confidently into Phase II clinical development, as planned, later this year.”

The Phase II study plan has been adopted by the NHS National Institute for Health Research Stroke Research Network (SRN). This important endorsement will enable ReNeuron to work closely with the SRN to optimise performance against defined targets regarding site set-up, patient recruitment and monitoring activities across the various sites participating in the study.

ReNeuron will seek final regulatory and ethical approvals for the Phase II stroke study by submitting a data package including three month follow-up data on the final dose cohort in the PISCES study to the UK regulatory authorities in early July and, assuming approvals are granted, expects to commence recruitment into the Phase II study shortly thereafter.

The PISCES study is the world’s first fully-regulated clinical trial of a neural stem cell therapy for disabled stroke patients. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world. The trial is being conducted at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Funding Boost for Precision Medicine Research in Glasgow
The University of Glasgow’s position as a leading centre for the development of precision medicine has been bolstered by the award of £3.4 million from the Medical Research Council and the Engineering and Physical Sciences Research Council (EPSRC) to create the largest MRC Molecular Pathology Node in the UK.
Tuesday, July 28, 2015
Scientific News
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Rapidly Generating Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
New Mechanism of Tuberculosis Infection
Researchers have identified a new infection mechanism of tuberculosis that could lead to a new therapeutic angle.
Modelling ALS Requires ‘Aged’ Stem Cells
Research suggests engineered cells are too ‘young’ to accurately model ALS and should be 'aged' to speed progress toward finding potential treatments.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
HIV Hides No Longer
Researchers are working to create proteins that clear HIV-infected cells in order to eliminate latent infection and dormancy.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!